Daily close, T-120 (5/5/25) through T+5. Run-up high $106.55 on 7/11/25, low $79.92 on 9/26/25 (T-120 to T-1). FDA decision 10/20/25. Historical price action, not a forecast.
Positioning before the decision
On Oct 6, 2025, 14 days before the decision date, at-the-money options priced a move of ±17.5% through Nov 21, 2025 (the first listed expiry after the decision; ATM implied volatility 62%). The stock closed -8.8% at the first close across the decision and -14.3% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Yes. The FDA approved the application for Epioxa (Epi-on) on October 20, 2025. The primary source is linked on this page.
What was Epioxa (Epi-on) under FDA review for?
The application covered Progressive keratoconus. The FDA approved the application on October 20, 2025.
How did GKOS stock react to the FDA decision?
On the decision day GKOS moved -8.8%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.